Zolpidem-Associated Hallucinations and Serotonin Reuptake Inhibition: A Possible Interaction

References

• George P, Rossey G, Depoortere H, Mompon B, Allen J, Wick A. Zolpidem and related compounds: Syntheses, physical properties and structure-activity relationships. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 11–24
   Google Scholar
• The Merck Index, 11th edition, S Budavare, MJ O'Neil, A Smith, PE Heckelman. Merck & Co., Inc., Whitehouse Station, NJ 1989
   Google Scholar
• RTECS Registry of Toxic Effects of Chemical Substances. National Institute for Occupational Safety and Health. Micromedex Inc., Cincinnati, Ohio, (CDROM version) Englewood, Colorado, (expiration date: 1/31/98)
   Google Scholar
• Langer S Z, Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors: A proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 1988; 29: 763–766
   PubMed Web of Science ®Google Scholar
• Langer S Z, Arbilla S, Scatton B, Niddam R, Dubois A. Receptors involved in the mechanism of action of Zolpidem. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 55–70
   Google Scholar
• Sanger D J, Benavides J, Perrault G. Recent developments in the behavioral pharmacology of benzodiazepine (co) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994; 18: 355–372
   PubMed Web of Science ®Google Scholar
• Benavides J, Peny B, Dubois A. In vivo interaction of Zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15–1788) in the mouse brain. Preferential affinity of Zolpidem for the ω1 (BZD1) subtype. J Pharmacol Exp Ther 1988; 245: 1033–1041
   PubMed Web of Science ®Google Scholar
• Dennis T, Dubois A, Benavides J, Scatton B. Distribution of central ω1 (benzodiazepinel) and ω2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]-flunitrazepam and the ω1 selective ligand [3H]zolpi-dem. J Pharmacol Exp Ther 1988; 247: 309–323
   PubMedGoogle Scholar
• Guidotti A, Berkovich A, Ferrarese C, Santi M R, Costa E. Neuronal-glial differential processing of DBI to yield ligands to central or peripheral benzodiazepine recognition sites. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 25–38
   Google Scholar
• Itier V, Depoortere H, Scatton B, Avenet P. Zolpidem functionally discriminates subtypes of native GABAA receptors in acutely dissociated rat striatal and cerebellar neurons. Neuropharmacology 1996; 35: 137–145
   PubMed Web of Science ®Google Scholar
• Lloyd K G, Zivkovic B. Specificity within the GABAA receptor supramolecular complex: A consideration of the new ω1-receptor selective imidazopyri-dine hypnotic Zolpidem. Pharmacol Biochem Behav 1988; 29: 781–783
   PubMed Web of Science ®Google Scholar
• Sieghart W. Heterogeneity of benzodiazepine receptors. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 39–45
   Google Scholar
• Lheureux P, Debailleul G, De Witte O, Askenasi R. Zolpidem intoxication mimicking narcotic overdose: Response to flumazenil. Hum Exp Toxicol 1990; 9: 105–107
   PubMed Web of Science ®Google Scholar
• Patat A, Naef M M, Van Gessel E, Forster A, Dubruc C, Rosenzweig P. Flumazenil antagonizes the central effects of Zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 1994; 56: 430–436
   PubMed Web of Science ®Google Scholar
• McKernan R M, Wafford K, Quirk K. The pharmacology of the benzodiazepine site of the GABA-A receptor is dependent on the type of y-subunit present. J Recept Signal Transduct Res 1995; 15: 173–183
   PubMed Web of Science ®Google Scholar
• Pritchett D B, Seeburg PH. -γ-Aminobutyric acidA receptor α5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 1990; 54: 1802–1804
   PubMed Web of Science ®Google Scholar
• Scatton B, Claustre Y, Dennis T, Nishikawa T. Zolpidem, a novel nonbenzodiazepine hypnotic. II. Effects on cerebellar cyclic GMP levels and cerebral monoamines. J Pharmacol Exp Ther 1986; 237: 659–665
   PubMed Web of Science ®Google Scholar
• Bartholini G. Growing aspects of hypnotic drugs. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 1–9
   Google Scholar
• Depoortere H, Zivkovic B, Lloyd K G. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuro-pharmacological and behavioral effects. J Pharmacol Exp Ther 1986; 237: 649–658
   PubMed Web of Science ®Google Scholar
• Gaillard J M, Kafi-de St-Hilaire S, Blois R. Pharmacological considerations on sleep mechanisms. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 71–80
   Google Scholar
• Sanger D J, Joly D, Zivkovic B. The behavioral pharmacology of Zolpidem: Comparisons with other compounds acting at the benzodiazepine receptor. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 111–121
   Google Scholar
• Sanger D J, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplonand Zolpidem. Eur J Pharmacol 1996; 313: 35–42
   PubMed Web of Science ®Google Scholar
• Zivkovic B, Perrault G, Morel E, Sanger DJ. Comparative pharmacology of Zolpidem and other hypnotics and sleep inducers. Imidazopyridines in Sleep Disorders: A Novel Experimental and Tlierapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 87–108
   Google Scholar
• Dockhorn R J, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: A randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1996; 19: 333–340
   PubMed Web of Science ®Google Scholar
• Palminteri R, Narbonne G. Safety profile of Zolpidem. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 351–361
   Google Scholar
• Scharf M B, Kaffeman M, Rodgers L, Segal J. Single dose tolerance study of Zolpidem. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 175–181
   Google Scholar
• Abadie P, Rioux P, Scatton B. Central benzodiazepine receptor occupancy by Zolpidem in the human brain as assessed by positron emission tomography. Eur J Pharmacol 1996; 295: 35–44
   PubMed Web of Science ®Google Scholar
• Byrnes J J, Greenblatt DJ, Miller LG. Benzodiazepine receptor binding of nonbenzodiazepinesin vivo: Alpidem, Zolpidem and zopiclone. Brain Res Bull 1992; 29: 905–908
   PubMed Web of Science ®Google Scholar
• Evans S M, Funderburk F R, Griffiths RR. Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990; 255: 1246–1255
   PubMed Web of Science ®Google Scholar
• Gillin J C, Buchsbaum M S, Valladares-Neto D C. Effects of Zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: A positron emission tomography study. Neuropsycho-pharmacology 1996; 15: 302–313
   PubMed Web of Science ®Google Scholar
• Piercey M F, Hoffmann W E, Cooper M. The hypnotics triazolam and Zolpidem have identical metabolic effects throughout the brain: Implications for benzodiazepine receptor subtypes. Brain Res 1991; 554: 244–252
   PubMed Web of Science ®Google Scholar
• Rush C R, Griffiths RR. Zolpidem, triazolam and temazepam: Behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996; 16: 146–157
   PubMed Web of Science ®Google Scholar
• Schmid L, Bottlaender M, Fuseau C, Fournier D, Brouillet E, Maziere M. Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor. in vivo. J Neurochem 1995; 65: 1880–1886
   PubMed Web of Science ®Google Scholar
• Ganzoni E, Santoni J P, Chevillard V, Sebille M, Mathy B. Zolpidem in insomnia: A 3-year postmarketing surveillance study in Switzerland. J Int Med Res 1995; 23: 61–73
   PubMed Web of Science ®Google Scholar
• Gamier R, Guerault E, Muzard D, Azoyan P, Chau-met-Riffaud A E, Efthymiou ML. Acute Zolpidem poisoning–analysis of 344 cases. J Toxicol Clin Toxicol 1994; 32: 391–404
   PubMedGoogle Scholar
• Maarek L, Cramer P, Attali P, Coquelin J P, Morselli PL. The safety and efficacy of Zolpidem in insomniac patients: A long-term open study in general practice. J Int Med Res 1992; 20: 162–170
   PubMed Web of Science ®Google Scholar
• Scharf M B, Roth T, Vogel G, Walsh JK. A multi-center, placebo-controlled study evaluating Zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994; 55: 192–199
   PubMed Web of Science ®Google Scholar
• Ansseau M, Pitchot W, Hansenne M, Gonzales-Moreno A. Psychotic reactions to Zolpidem. Lancet 1992; 339: 809
   PubMed Web of Science ®Google Scholar
• Iruela L M, Ibanez-Rojo V, Baca E. Zolpidem-induced macropsiain anorexic woman. Lancet 1993; 342: 443–444
   PubMed Web of Science ®Google Scholar
• Iruela L M, Ibafiez-Rojo V, Baca E. More on Zolpidem side-effects. Lancet 1993; 342: 1495–1496
   PubMed Web of Science ®Google Scholar
• Katz SE. Possible paroxetine-zolpidem interaction. Lancet 1995; 152: 1689
   Google Scholar
• Markowitz J S, Brewerton TD. Zolpidem-induced psychosis. Ann Gin Psychiatry 1996; 8: 89–91
   PubMedGoogle Scholar
• Markowitz J S, Rames L J, Reeves N, Thomas SG. Zolpidem and hallucinations. Ann Etnerg Med 1997; 29: 300–301
   PubMed Web of Science ®Google Scholar
• Morselli PL. Zolpidem side-effects. Lancet 1993; 342: 868–869
   PubMed Web of Science ®Google Scholar
• Pies RW. Dose-related sensory distortions with Zolpidem. J Clin Psychiatry 1995; 56: 35–36
   PubMed Web of Science ®Google Scholar
• Van Puijenbroek E P, Egberts A C, Krom HJ. Visual hallucinations and amnesia associated with the use of Zolpidem. IntJ Clin Pharmacol Ther 1996; 34: 318
   PubMed Web of Science ®Google Scholar
• Kurta D L, Myers L B, Krenzelok EP. Zolpidem (Ambien): A pediatric case series. J Toxicol Clin Toxicol 1997; 35: 453–457
   PubMed Web of Science ®Google Scholar
• Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of Zolpidem. Clin Pharmacokinet 1995; 29: 142–153
   PubMed Web of Science ®Google Scholar
• Piergies A A, Sweet J, Johnson M, Roth-Schechter B F, Allard S. The effect of co-administration of Zolpidem with fluoxetine: Pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996; 34: 178–183
   PubMed Web of Science ®Google Scholar
• Desager J P, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Possible interactions between Zolpidem, a new sleep inducer and chlorpromazine, aphenothiazineneuroleptic. Psychopharmacology 1988; 96: 63–66
   PubMed Web of Science ®Google Scholar
• Harvengt C, Hulhoven R, Desager J P. Drug interactions investigated with Zolpidem. Imidazo-pyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, JP Sauvanet, SZ Langer, PL Morselli. Raven Press Ltd., New York 1988; 165–173
   Google Scholar
• Hulhoven R, Desager J P, Harvengt C, Hermann P, Guillet P, Thiercelin JF. Lack of interaction between Zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Ther 1988; 8: 471–476
   Web of Science ®Google Scholar